PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 16, 2018Diabetes Care221 citationsOpen Access

Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial

CRCristina RazquínETEstefanía ToledoCCClary B. Clish

Key Points

Key points are not available for this paper at this time.

Abstract

OBJECTIVE: Specific lipid molecular changes leading to type 2 diabetes (T2D) are largely unknown. We assessed lipidome factors associated with future occurrence of T2D in a population at high cardiovascular risk. RESEARCH DESIGN AND METHODS: We conducted a case-cohort study nested within the PREDIMED trial, with 250 incident T2D cases diagnosed during 3.8 years of median follow-up, and a random sample of 692 participants (639 noncases and 53 overlapping cases) without T2D at baseline. We repeatedly measured 207 plasma known lipid metabolites at baseline and after 1 year of follow-up. We built combined factors of lipid species using principal component analysis and assessed the association between these lipid factors (or their 1-year changes) and T2D incidence. RESULTS: for linear trend <0.001 for all). One-year changes in these lipids showed associations in similar directions but were not significant after adjustment for baseline levels. TAGs with odd-chain fatty acids showed inverse associations with T2D after adjusting for total TAGs. CONCLUSIONS: Two plasma lipid profiles made up of different lipid classes were found to be associated with T2D in participants at high cardiovascular risk. A profile including LPs, PC-PLs, SMs, and CEs was associated with lower T2D risk. Another profile composed of TAGs, DAGs, and PEs was associated with higher T2D risk.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Razquín et al. (2018) studied this question.

synapsesocial.com/papers/6a04ddeb3cbeb1d267ef8464https://doi.org/10.2337/dc18-0840
Ask AI
Helpful
Bookmark
Share
View Full Paper